Search Results - "Therapeutic approach"
Suggested Topics within your search.
Suggested Topics within your search.
- Cancer
- Prostate 4
- Antineoplastic Agents 3
- Antineoplastic agents 3
- Carcinoma, Renal Cell 3
- Chemotherapy 3
- Diseases 3
- Down-Regulation 3
- Drug Resistance, Neoplasm 3
- Drug resistance in cancer cells 3
- Genetic aspects 3
- Genetics 3
- Genetics, Medical 3
- Kidney Diseases 3
- Kidney Neoplasms 3
- Kidneys 3
- Medical genetics 3
- Metabolic Diseases 3
- Mitochondria 3
- Oxidative Phosphorylation 3
- Prostatic Neoplasms 3
- Receptors, Androgen 3
- Renal cell carcinoma 3
- S-Phase Kinase-Associated Proteins 3
- drug effects 3
- drug therapy 3
- metabolism 3
- pathology 3
- pharmacology 3
- therapeutic use 3
-
1
Mitochondrial inhibition as a novel therapeutic approach in drug-resistant cancer
Published 2017Get full text
Electronic Video -
2
Mitochondrial inhibition as a novel therapeutic approach in drug-resistant cancer
Published 2017Get full text
Electronic Video -
3
Mitochondrial inhibition as a novel therapeutic approach in drug-resistant cancer
Published 2017Get full text
Electronic Video -
4
Prostate cancer basic mechanisms and therapeutic approaches /
Published 2005An electronic book accessible through the World Wide Web; click to view
Electronic eBook -
5
The genetic basis of kidney cancer
Published 2014Table of Contents: “…Contents: Renal carcinoma -- Stage I , Stage IV Kidney Cancer -- Human renal epithelial neoplasms -- Loss of alleles in Renal Cell Carcinoma -- Mapping the minimal 3p loss region in Clear Cell Renal Carcinoma -- Studying cancer families to identify renal carcinoma genes -- Identification of kidney cancer genes -- Inherited forms of renal carcinoma -- Clear cell Renal Carcinoma: von Hippel Lindau (VHL) -- VHL gene -- VHL gene localization map -- Germline VHL mutations -- Papillary Renal Carcinoma -- Mouse studies of VHL gene -- VHL gene function -- HIFα -- Downstream effects of VHL mutation -- Targeting VHL/HIF in Clear Cell RCC -- TCGA Clear Cell Kidney Cancer -- Intratumor heterogeneity -- Warburg effect in Clear Cell Kidney Cancer -- Non-Clear Cell RCC -- Locally advanced Kidney Cancer -- Hereditary Papillary Renal Carcinoma (HPRC) -- Inherited Renal Carcinoma -- Type 1 Papillary Renal Carcinoma -- Penetrance of MET mutation H1210R -- MET gene: Type 1 Papillary RCC -- Location of the HPRC gene -- HPRC: Activating mutations in the Tyrosine Kinase domain of MET -- Location of MET mutations in the HPRC patients -- Targeting MET RCC gene pathway -- Potential small molecule target: MET Tyrosine Kinase inhibition -- Foretinib: Dual VEGFR and MET Inhibitor -- MiT Kidney Cancer TFE3, TFEB, MITF -- UOK124, Papillary Kidney Cancer -- UOK124, UOK120, UOK 146 & TFE3 Kidney Cancer -- Inherited Renal Carcinoma Birt-Hogg-Dubé (BHD) -- Birt Hogg Dubé cutaneous manifestations -- Kidney tumors in BHD -- BHD renal tumor pathology -- BHD lung cysts -- Identification of the BHD Gene -- Cutaneous Fibrofolliculomas -- BHD Gene: Chromophobe RCC -- BHD Gene Locus: Chromosome 17 -- BHD Protein Sequence -- FLCN Mutation Spectrum -- Therapeutic Approach: What Kind of Gene is FLCN? -- BHD Gene Analysis in BHD-Associated RCC -- Somatic mutations in renal Tumors from BHD patients -- UOK 257, BHD -/- RCC cell line study -- How does the FLCN gene function? …”
Get full text
Series (Molecular genetics of human disease)
Series (Kidney in health and disease)
Electronic Video -
6
The genetic basis of kidney cancer
Published 2014Table of Contents: “…Contents: Renal carcinoma -- Stage I , Stage IV Kidney Cancer -- Human renal epithelial neoplasms -- Loss of alleles in Renal Cell Carcinoma -- Mapping the minimal 3p loss region in Clear Cell Renal Carcinoma -- Studying cancer families to identify renal carcinoma genes -- Identification of kidney cancer genes -- Inherited forms of renal carcinoma -- Clear cell Renal Carcinoma: von Hippel Lindau (VHL) -- VHL gene -- VHL gene localization map -- Germline VHL mutations -- Papillary Renal Carcinoma -- Mouse studies of VHL gene -- VHL gene function -- HIFα -- Downstream effects of VHL mutation -- Targeting VHL/HIF in Clear Cell RCC -- TCGA Clear Cell Kidney Cancer -- Intratumor heterogeneity -- Warburg effect in Clear Cell Kidney Cancer -- Non-Clear Cell RCC -- Locally advanced Kidney Cancer -- Hereditary Papillary Renal Carcinoma (HPRC) -- Inherited Renal Carcinoma -- Type 1 Papillary Renal Carcinoma -- Penetrance of MET mutation H1210R -- MET gene: Type 1 Papillary RCC -- Location of the HPRC gene -- HPRC: Activating mutations in the Tyrosine Kinase domain of MET -- Location of MET mutations in the HPRC patients -- Targeting MET RCC gene pathway -- Potential small molecule target: MET Tyrosine Kinase inhibition -- Foretinib: Dual VEGFR and MET Inhibitor -- MiT Kidney Cancer TFE3, TFEB, MITF -- UOK124, Papillary Kidney Cancer -- UOK124, UOK120, UOK 146 & TFE3 Kidney Cancer -- Inherited Renal Carcinoma Birt-Hogg-Dubé (BHD) -- Birt Hogg Dubé cutaneous manifestations -- Kidney tumors in BHD -- BHD renal tumor pathology -- BHD lung cysts -- Identification of the BHD Gene -- Cutaneous Fibrofolliculomas -- BHD Gene: Chromophobe RCC -- BHD Gene Locus: Chromosome 17 -- BHD Protein Sequence -- FLCN Mutation Spectrum -- Therapeutic Approach: What Kind of Gene is FLCN? -- BHD Gene Analysis in BHD-Associated RCC -- Somatic mutations in renal Tumors from BHD patients -- UOK 257, BHD -/- RCC cell line study -- How does the FLCN gene function? …”
Get full text
Series (Molecular genetics of human disease)
Series (Kidney in health and disease)
Electronic Video -
7
The genetic basis of kidney cancer
Published 2014Table of Contents: “…Contents: Renal carcinoma -- Stage I , Stage IV Kidney Cancer -- Human renal epithelial neoplasms -- Loss of alleles in Renal Cell Carcinoma -- Mapping the minimal 3p loss region in Clear Cell Renal Carcinoma -- Studying cancer families to identify renal carcinoma genes -- Identification of kidney cancer genes -- Inherited forms of renal carcinoma -- Clear cell Renal Carcinoma: von Hippel Lindau (VHL) -- VHL gene -- VHL gene localization map -- Germline VHL mutations -- Papillary Renal Carcinoma -- Mouse studies of VHL gene -- VHL gene function -- HIFα -- Downstream effects of VHL mutation -- Targeting VHL/HIF in Clear Cell RCC -- TCGA Clear Cell Kidney Cancer -- Intratumor heterogeneity -- Warburg effect in Clear Cell Kidney Cancer -- Non-Clear Cell RCC -- Locally advanced Kidney Cancer -- Hereditary Papillary Renal Carcinoma (HPRC) -- Inherited Renal Carcinoma -- Type 1 Papillary Renal Carcinoma -- Penetrance of MET mutation H1210R -- MET gene: Type 1 Papillary RCC -- Location of the HPRC gene -- HPRC: Activating mutations in the Tyrosine Kinase domain of MET -- Location of MET mutations in the HPRC patients -- Targeting MET RCC gene pathway -- Potential small molecule target: MET Tyrosine Kinase inhibition -- Foretinib: Dual VEGFR and MET Inhibitor -- MiT Kidney Cancer TFE3, TFEB, MITF -- UOK124, Papillary Kidney Cancer -- UOK124, UOK120, UOK 146 & TFE3 Kidney Cancer -- Inherited Renal Carcinoma Birt-Hogg-Dubé (BHD) -- Birt Hogg Dubé cutaneous manifestations -- Kidney tumors in BHD -- BHD renal tumor pathology -- BHD lung cysts -- Identification of the BHD Gene -- Cutaneous Fibrofolliculomas -- BHD Gene: Chromophobe RCC -- BHD Gene Locus: Chromosome 17 -- BHD Protein Sequence -- FLCN Mutation Spectrum -- Therapeutic Approach: What Kind of Gene is FLCN? -- BHD Gene Analysis in BHD-Associated RCC -- Somatic mutations in renal Tumors from BHD patients -- UOK 257, BHD -/- RCC cell line study -- How does the FLCN gene function? …”
Get full text
Series (Molecular genetics of human disease)
Series (Kidney in health and disease)
Electronic Video
